McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M et al (2021) Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 42(48):4901
van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH (2014) Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 16(7):772–777
Stretti L, Zippo D, Coats AJS, Anker MS, von Haehling S, Metra M et al (2021) A year in heart failure: an update of recent findings. ESC Heart Fail 8(6):4370–4393
Article PubMed PubMed Central Google Scholar
van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH (2016) Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 18(3):242–52
Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E et al (2020) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 22(3):391–412
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP et al (2017) Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19(12):1574–1585
Article PubMed CAS Google Scholar
Lewis EF, Lamas GA, O’Meara E, Granger CB, Dunlap ME, McKelvie RS et al (2007) Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail 9(1):83–91
Zile MR, Kjellstrom B, Bennett T, Cho Y, Baicu CF, Aaron MF et al (2013) Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circ Heart Fail 6(3):508–516
Article PubMed CAS Google Scholar
Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ et al (2009) Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 119(24):3070–3077
Article PubMed PubMed Central Google Scholar
Chan MM, Lam CS (2013) How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 15(6):604–613
Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M et al (2008) Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 29(3):339–347
Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR et al (2018) Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail 6(8):678–685
Article PubMed PubMed Central Google Scholar
Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R et al (2015) A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 175(6):996–1004
Article PubMed PubMed Central Google Scholar
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777–781
Article PubMed CAS Google Scholar
Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J et al (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338–2345
Article PubMed CAS Google Scholar
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383–1392
Article PubMed CAS Google Scholar
van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M et al (2009) Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53(23):2150–2158
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609–1620
Article PubMed CAS Google Scholar
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456–2467
Article PubMed CAS Google Scholar
Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW et al (2006) Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary Digitalis Investigation Group trial. Circulation 114(5):397–403
Article PubMed PubMed Central CAS Google Scholar
Tomasoni D, Adamo M, Lombardi CM, Metra M (2019) Highlights in heart failure. ESC Heart Fail 6(6):1105–1127
Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M (2020) Heart failure in the last year: progress and perspective. ESC Heart Fail
Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS et al (2022) Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail 24(3):431–441
Article PubMed CAS Google Scholar
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451–1461
Article PubMed CAS Google Scholar
Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F et al (2021) The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 27(11):1954–1960
Article PubMed PubMed Central Google Scholar
Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN et al (2021) Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail 23(7):1217–1225
Article PubMed CAS Google Scholar
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med
Fudim M, Abraham WT, von Bardeleben RS, Lindenfeld J, Ponikowski PP, Salah HM et al (2021) Device therapy in chronic heart failure: JACC state-of-the-art review. J Am Coll Cardiol 78(9):931–956
Maeder MT, Kaye DM (2009) Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 53(11):905–918
Zile MR, Baicu CF, Gaasch WH (2004) Diastolic heart failure–abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350(19):1953–1959
Article PubMed CAS Google Scholar
Borlaug BA (2014) The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 11(9):507–515
Article PubMed CAS Google Scholar
Feldman T, Mauri L, Kahwash R, Litwin S, Ricciardi MJ, van der Harst P et al (2018) Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): a phase 2, randomized, sham-controlled trial. Circulation 137(4):364–375
Wolsk E, Kaye D, Borlaug BA, Burkhoff D, Kitzman DW, Komtebedde J et al (2018) Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 20(4):715–722
Iacovoni A, Palmieri V, Abete R, Vecchi AL, Mortara A, Gori M et al (2022) Right and left ventricular structures and functions in acute HFpEF: comparing the hypertensive pulmonary edema and worsening heart failure phenotypes. J Cardiovasc Med (Hagerstown) 23(10):663–671
Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ (2018) Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J 39(30):2780–2792
Article PubMed CAS Google Scholar
Dorfs S, Zeh W, Hochholzer W, Jander N, Kienzle RP, Pieske B et al (2014) Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J 35(44):3103–3112
Article PubMed CAS Google Scholar
Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C et al (2014) Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 7(6):935–944
Shavelle DM, Desai AS, Abraham WT, Bourge RC, Raval N, Rathman LD et al (2020) Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the CardioMEMS post-approval study. Circ Heart Fail 13(8):e006863
留言 (0)